Recently, it was reported that NLRP3 inflammasome inhibition could be one of the mechanisms underlying metformin’s effects to inhibit diabetes-accelerated atherosclerosis (Tang et al., 2019). This evidence concerns the gene NLRP3 and atherosclerosis.